The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
about
Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysisMiRNAs and miRNA Polymorphisms Modify Drug ResponseReciprocal regulation between microRNAs and epigenetic machinery in colorectal cancer.Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patientsMicroRNA binding site polymorphisms as biomarkers in cancer management and research.The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.MicroRNA-mediated regulation of KRAS in cancerInterplay between 3'-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans.Genetic variants in 3'-UTRs of methylenetetrahydrofolate reductase (MTHFR) predict colorectal cancer susceptibility in Koreans.Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men.Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer.Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathwayMicroRNAs targeting EGFR signalling pathway in colorectal cancer.Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.Polymorphisms in Non-coding RNA Genes and Their Targets Sites as Risk Factors of Sporadic Colorectal Cancer.KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective.Identification of a functional polymorphism affecting microRNA binding in the susceptibility locus 1q25.3 for colorectal cancer.A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.Overlapping effects of genetic variation and epigenetics on drug response: challenges of pharmacoepigenomics.Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer.A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.Tumor exosomes: a double-edged sword in cancer therapy.Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma.Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.
P2860
Q26827474-3DEC1A7E-1FAE-48AA-9930-05A43A0FC022Q28079075-3627DB28-709B-4404-813E-19CF1F55B2FDQ33599015-FD81506F-9500-4E7A-999F-9D990FD8D60BQ33855053-0188ADB3-C547-4D99-BA76-DDFB1CA73A6DQ33861210-D3F0E15C-0DB6-491B-B6AA-63901468C035Q34019040-721B45B2-5D52-4A31-8ACD-A083F943E42DQ34134870-FF4B4C4A-AEF5-48A8-9B8C-D127E911D9E4Q34138308-B09A4680-FE16-4242-BE3D-D4CFF299F832Q34678120-2499A607-821F-4200-85CB-184ECCE5841BQ34894525-012F57F9-FC53-4F22-A396-6CBA375940F2Q35687058-D7A8156D-796E-4674-8F5C-79CA8441216EQ36000232-97C1920A-7177-47C2-9053-FDA65202877CQ36228676-C54EA07F-C171-46C2-973E-32E3D7292669Q36847230-304CB172-4DBC-472B-8972-1715087DF30AQ37604560-8227F1B9-28A4-4C32-A561-82620317D337Q38118612-C7E6E868-DC07-4025-87E9-0421BB01C540Q38172182-F31E6EC9-22C7-47E7-B280-4E4D4B446CA5Q38545768-FF4CFF7F-CC42-4DFB-9A0D-BA3412A92317Q38940602-215CE5D0-26CB-41F9-8A01-B636D132CF9BQ38985125-4D791C49-16BE-46CF-B03F-141875111B18Q39023377-300A2F10-229C-49E9-B5FE-076F493A3BCFQ39381552-0423DC51-9A53-40FF-85C5-DBF35CD04F0BQ40300140-C3FC5C26-0629-42ED-A3C9-086B31E0AF00Q40492655-3D044383-7304-4930-96D2-E7AD15BD3CAEQ43568484-1CEB486F-537C-4FB3-BEF9-3CA40F654FE4Q47761632-83A07617-1B3B-423D-BCBA-4E68E4B23A75Q50943511-BCA4B63A-4013-4F09-9DE7-4696C4AB49D4Q52654592-E3DA08C2-13B9-4AE5-BD9A-D12536771036Q54245253-F0529564-1F32-4A2D-A899-7696F29D482CQ55067016-5ACB5E1A-88D9-47E4-ABD0-E267C5818E6D
P2860
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The LCS6 polymorphism in the b ...... ic colorectal cancer patients.
@en
The LCS6 polymorphism in the b ...... ic colorectal cancer patients.
@nl
type
label
The LCS6 polymorphism in the b ...... ic colorectal cancer patients.
@en
The LCS6 polymorphism in the b ...... ic colorectal cancer patients.
@nl
prefLabel
The LCS6 polymorphism in the b ...... ic colorectal cancer patients.
@en
The LCS6 polymorphism in the b ...... ic colorectal cancer patients.
@nl
P2093
P1476
The LCS6 polymorphism in the b ...... ic colorectal cancer patients.
@en
P2093
Agustí Barnadas
Alan González
David Páez
Elisabeth del Río
Juliana Salazar
Marta Martín-Richard
María Tobeña
Montserrat Baiget
P304
P356
10.1097/FPC.0B013E32835D9B0B
P577
2013-03-01T00:00:00Z